Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Tohru Hasegawa

Tohru Hasegawa

Saga Woman Junior College, Japan

Title: Targeting therapy for homocysteic acid in blood is an Alzheimer’s cognitive recovery

Biography

Biography: Tohru Hasegawa

Abstract

At present we have no hope to recover the Alzheimer cognitive impairment. Just only an intervention which combines an exercise with DHA supplement establishes to recover the cognition. It is interested in DHA supplement combination. Many hypothesises are considered why these interventions can recover the cognitive decline in AD. The exercise indeed stimulates the blood circulation which induces the urinary excretion of blood unknown pathogens for the cognitive impairment and consequently some recovery can be observed. We hypothesize that the homocysteic acid in blood is the one of pathogens which are excreted into urine. Why is DHA supplement needed for the recovery process induced by an exercise? DHA is known to decrease homocysteine level and exercise contributes DHA effect. In other words, the combination of exercise and DHA induces the strong decrease of homocysteine in blood, which supports our hypothesis, the targeting homocysteic acid in blood is a possible method which can recover an Alzheimer cognitive impairment. Our hypothesis was proved by the fact that the memorial problem of 3xTg- AD model mice which were developed by amyloid pathology and the model for the familial AD were recovered by anti-HA antibody and not by amyloid treatment. Why did 3xTg-AD mice which increased amyloid pathology increase HA level? APP and/or presenilin increased calcium inflax which could increase superoxide level and consequently increase HA level from homocysteine or methionine. Also our hypothesis is partially supported by the open clinical trial of some supplement which can decrease the homocysteic acid in blood for Alzheimer’s patients and the result is very impressive.